| Some gating potentiators, including VX-770, diminish ΔF508-CFTR functional expression G Veit, RG Avramescu, D Perdomo, PW Phuan, M Bagdany, PM Apaja, ... Science translational medicine 6 (246), 246ra97-246ra97, 2014 | 326 | 2014 |
| Gene-edited stem cells enable CD33-directed immune therapy for myeloid malignancies F Borot, H Wang, Y Ma, T Jafarov, A Raza, AM Ali, S Mukherjee Proceedings of the National Academy of Sciences 116 (24), 11978-11987, 2019 | 111 | 2019 |
| Bone marrow myeloid cells regulate myeloid-biased hematopoietic stem cells via a histamine-dependent feedback loop X Chen, H Deng, MJ Churchill, LL Luchsinger, X Du, TH Chu, ... Cell stem cell 21 (6), 747-760. e7, 2017 | 88 | 2017 |
| CFTR in a lipid raft-TNFR1 complex modulates gap junctional intercellular communication and IL-8 secretion T Dudez, F Borot, S Huang, BR Kwak, M Bacchetta, M Ollero, BA Stanton, ... Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 1783 (5), 779-788, 2008 | 83 | 2008 |
| Membrane cholesterol content modulates ClC-2 gating and sensitivity to oxidative stress A Hinzpeter, J Fritsch, F Borot, S Trudel, DL Vieu, F Brouillard, ... Journal of Biological Chemistry 282 (4), 2423-2432, 2007 | 45 | 2007 |
| DNMT3a mutations in high-risk myelodysplastic syndrome parallel those found in acute myeloid leukemia. MS Ewalt M, Galili NG, Mumtaz M, Churchill M, Rivera S, Borot F, Raza A Blood Cancer J 1 (3), 2011 | 41 | 2011 |
| Eicosanoid release is increased by membrane destabilization and CFTR inhibition in Calu-3 cells F Borot, DL Vieu, G Faure, J Fritsch, J Colas, S Moriceau, ... PLoS One 4 (10), e7116, 2009 | 39 | 2009 |
| Control of basal CFTR gene expression by bicarbonate-sensitive adenylyl cyclase in human pulmonary cells M Baudouin-Legros, N Hamdaoui, F Borot, J Fritsch, M Ollero, G Planelles, ... Cellular Physiology and Biochemistry 21 (1-3), 075-086, 2008 | 36 | 2008 |
| Critical role of cytosolic phospholipase A2α in bronchial mucus hypersecretion in CFTR-deficient mice F Dif, YZ Wu, PR Burgel, M Ollero, D Leduc, J Aarbiou, F Borot, ... European Respiratory Journal 36 (5), 1120-1130, 2010 | 34 | 2010 |
| Subversion of serotonin receptor signaling in osteoblasts by kynurenine drives acute myeloid leukemia M Galán-Díez, F Borot, AM Ali, J Zhao, E Gil-Iturbe, X Shan, N Luo, Y Liu, ... Cancer discovery 12 (4), 1106-1127, 2022 | 21 | 2022 |
| Compositions and methods for inhibition of lineage specific antigens S Mukherjee, F Borot, AM Ali US Patent 10,137,155, 2018 | 17 | 2018 |
| Compositions and methods for inhibition of lineage specific antigens S Mukherjee, F Borot, AM Ali US Patent App. 16/451,906, 2019 | 13 | 2019 |
| Compositions and methods for inhibition of lineage specific antigens S Mukherjee, F Borot, AM Ali US Patent 10,912,799, 2021 | 12 | 2021 |
| Compositions and methods for inhibition of lineage specific antigens S Mukherjee, F Borot, AM Ali US Patent 10,668,103, 2020 | 12 | 2020 |
| Compositions and methods for inhibition of lineage specific antigens S Mukherjee, F Borot, AM Ali US Patent 10,660,919, 2020 | 11 | 2020 |
| Compositions and methods for inhibition of lineage specific antigens S Mukherjee, F Borot, AM Ali US Patent 10,786,535, 2020 | 10 | 2020 |
| Changes in lipid raft proteome upon TNF-α stimulation of cystic fibrosis cells C Chhuon, I Pranke, F Borot, D Tondelier, J Lipecka, J Fritsch, M Chanson, ... Journal of proteomics 145, 246-253, 2016 | 10 | 2016 |
| CD33 exon 2 deficient donor stem cells for use with CD33 targeting agents S Mukherjee, AM Ali, F Borot US Patent 11,718,659, 2023 | 9 | 2023 |
| Compositions and methods for inhibition of lineage specific antigens S Mukherjee, F Borot, AM Ali US Patent App. 17/243,987, 2021 | 8 | 2021 |
| Compositions and methods for inhibition of lineage specific antigens S Mukherjee, F Borot, AM Ali US Patent App. 17/244,136, 2021 | 7 | 2021 |
